Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CORMAC DENISE DEPAN

Allopathic & Osteopathic Physicians Otolaryngology Otolaryngology/Facial Plastic Surgery

NPI
1588823421
CMS profile
298355
Location
WORCESTER, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$113.89

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $113.89 5

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $37.09 2
Acclarent, Inc $32.32 1
Smith+Nephew, Inc. $26.75 1
OptiNose US, Inc. $17.73 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CORMAC DENISE DEPAN

NPI 1588823421 · CMS profile ID 298355

Allopathic & Osteopathic Physicians / Otolaryngology / Otolaryngology/Facial Plastic Surgery

WORCESTER, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588823421?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CORMAC DENISE DEPAN, NPI 1588823421, CMS profile ID 298355. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588823421?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CORMAC DENISE DEPAN, NPI 1588823421, CMS profile ID 298355. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588823421?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CORMAC DENISE DEPAN, NPI 1588823421, CMS profile ID 298355, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1588823421?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $113.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
OptiNose US, Inc. $17.7310/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684272741 CMS
E.R. Squibb & Sons, L.L.C. $17.8607/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651238787 CMS
E.R. Squibb & Sons, L.L.C. $19.2307/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651238785 CMS
Smith+Nephew, Inc. $26.7502/06/2019 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 699458205 CMS
Acclarent, Inc $32.3201/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648631209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $113.89 5
PY2020 $32.27 3
PY2023 $23.51 1
PY2024 $30.71 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $138,332.88 34
PY2023 Principal investigator $336,972.57 66
PY2022 Principal investigator $134,284.00 44
PY2021 Principal investigator $19,537.50 7
PY2020 Principal investigator $77,781.42 4
PY2019 Principal investigator $48,890.48 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $669.23 12/12/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127786461
Principal investigator 1 GlaxoSmithKline, LLC. $7,600.00 12/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127787808
Principal investigator 1 GlaxoSmithKline, LLC. $627.70 12/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127787810
Principal investigator 1 GlaxoSmithKline, LLC. $627.69 12/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127787812
Principal investigator 1 GlaxoSmithKline, LLC. $669.23 12/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127787816
Principal investigator 1 GlaxoSmithKline, LLC. $8,025.00 12/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127790496
Principal investigator 1 GlaxoSmithKline, LLC. $1,146.43 11/14/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203903
Principal investigator 1 GlaxoSmithKline, LLC. $1,164.29 11/14/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204365
Principal investigator 1 GlaxoSmithKline, LLC. $9,250.00 11/14/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127785831
Principal investigator 1 GlaxoSmithKline, LLC. $8,125.00 11/14/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127787806
Principal investigator 1 GlaxoSmithKline, LLC. $1,275.00 10/10/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203869
Principal investigator 1 GlaxoSmithKline, LLC. $9,050.00 10/10/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203881
Principal investigator 1 GlaxoSmithKline, LLC. $9,050.00 10/10/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1127787814
Principal investigator 1 GlaxoSmithKline, LLC. $8,250.00 09/12/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204323
Principal investigator 1 GlaxoSmithKline, LLC. $7,600.00 09/12/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204335
Principal investigator 1 GlaxoSmithKline, LLC. $1,919.00 09/12/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204345
Principal investigator 1 GlaxoSmithKline, LLC. $1,563.00 08/15/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006197923
Principal investigator 1 GlaxoSmithKline, LLC. $9,900.00 08/15/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203039
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 08/15/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203061
Principal investigator 1 GlaxoSmithKline, LLC. $9,550.00 08/15/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203415
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 08/15/2023 Non-covered Recipient Entity
BIOCLINICA INC
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1006203437
Principal investigator 1 GlaxoSmithKline, LLC. $1,593.00 08/15/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203859
Principal investigator 1 GlaxoSmithKline, LLC. $2,893.00 07/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203509
Principal investigator 1 GlaxoSmithKline, LLC. $22,100.00 07/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203479
Principal investigator 1 GlaxoSmithKline, LLC. $5,600.00 07/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203499
Principal investigator 1 GlaxoSmithKline, LLC. $22,675.00 07/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203521
Principal investigator 1 GlaxoSmithKline, LLC. $3,111.00 07/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203849
Principal investigator 1 GlaxoSmithKline, LLC. $3,006.00 07/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204355
Principal investigator 1 GlaxoSmithKline, LLC. $654.00 06/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006198007
Principal investigator 1 GlaxoSmithKline, LLC. $1,806.00 06/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203892
Principal investigator 1 GlaxoSmithKline, LLC. $1,714.00 06/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203933
Principal investigator 1 GlaxoSmithKline, LLC. $3,174.00 05/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006197985
Principal investigator 1 GlaxoSmithKline, LLC. $8,425.00 05/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203489
Principal investigator 1 GlaxoSmithKline, LLC. $9,850.00 05/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203943
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 05/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006204395
Principal investigator 1 GlaxoSmithKline, LLC. $12,300.00 04/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006198017
Principal investigator 1 GlaxoSmithKline, LLC. $9,925.00 04/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006202977
Principal investigator 1 GlaxoSmithKline, LLC. $912.00 04/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006202987
Principal investigator 1 GlaxoSmithKline, LLC. $2,105.00 04/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203457
Principal investigator 1 GlaxoSmithKline, LLC. $531.00 04/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203953
Principal investigator 1 GlaxoSmithKline, LLC. $2,075.00 04/13/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006204311
Principal investigator 1 GlaxoSmithKline, LLC. $201.00 04/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006197965
Principal investigator 1 GlaxoSmithKline, LLC. $7,950.00 04/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203469
Principal investigator 1 GlaxoSmithKline, LLC. $625.00 04/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203913
Principal investigator 1 GlaxoSmithKline, LLC. $11,225.00 04/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204291
Principal investigator 1 GlaxoSmithKline, LLC. $3,980.00 04/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204375
Principal investigator 1 GlaxoSmithKline, LLC. $2,402.00 04/11/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204385
Principal investigator 1 GlaxoSmithKline, LLC. $12,125.00 04/05/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203049
Principal investigator 1 GlaxoSmithKline, LLC. $320.00 03/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006197975
Principal investigator 1 GlaxoSmithKline, LLC. $9,700.00 03/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006197997
Principal investigator 1 GlaxoSmithKline, LLC. $1,330.00 03/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006202599
Principal investigator 1 GlaxoSmithKline, LLC. $7,775.00 03/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006202609
Principal investigator 1 GlaxoSmithKline, LLC. $615.00 03/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006202955
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 03/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006202965
Principal investigator 1 GlaxoSmithKline, LLC. $1,753.00 02/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006197933
Principal investigator 1 GlaxoSmithKline, LLC. $6,300.00 02/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006197943
Principal investigator 1 GlaxoSmithKline, LLC. $3,400.00 02/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006197953
Principal investigator 1 GlaxoSmithKline, LLC. $4,500.00 02/16/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203021
Principal investigator 1 GlaxoSmithKline, LLC. $822.00 02/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203923
Principal investigator 1 GlaxoSmithKline, LLC. $1,560.00 02/16/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006204301
Principal investigator 1 GlaxoSmithKline, LLC. $1,625.00 01/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006202999
Principal investigator 1 GlaxoSmithKline, LLC. $9,633.00 01/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203009
Principal investigator 1 GlaxoSmithKline, LLC. $2,010.00 01/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203029
Principal investigator 1 GlaxoSmithKline, LLC. $8,525.00 01/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP PHASE III STUDY TO ASSESS T No dispute reported 06/30/2026 1006203427
Principal investigator 1 GlaxoSmithKline, LLC. $1,161.00 01/12/2023 Non-covered Recipient Entity
BIOCLINICA INC
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE I No dispute reported 06/30/2026 1006203447
Principal investigator 1 AstraZeneca UK Limited $23,025.00 01/03/2023 Non-covered Recipient Entity
GI REVIEWERS LLC
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID) No dispute reported 06/30/2026 991130019